Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 3/20 | 0.37 |
| ▸ | FLT4 | P35916 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157722 | 0.86 | CYP3A4 (0.46) | CYP3A4TSHRCASP1SMN1; SMN2SLC6A2 | |
| SCHEMBL2158295 | 0.81 | CYP3A4 (0.41) | CYP3A4TSHRCASP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2158071 | 0.78 | HSD17B1 (0.43) | CYP3A4TSHRSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL1959495 | 0.75 | TSHR (0.42) | CYP3A4TSHRCASP1SMN1; SMN2SLC6A2 | |
| SCHEMBL6017639 | 0.73 | TSHR (0.43) | CYP3A4TSHRCASP1SMN1; SMN2SLC6A2 | |
| SCHEMBL1961039 | 0.72 | FLT1 (0.39) | CYP3A4SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6627206 | 0.71 | PDK1 (0.44) | CYP3A4TSHRCASP1SMN1; SMN2FLT1 | |
| SCHEMBL4159892 | 0.70 | MAPT (0.45) | CYP3A4SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL2157949 | 0.69 | POLB (0.45) | ALDH1A1 | |
| SCHEMBL13270806 | 0.69 | SMN1; SMN2 (0.41) | CYP3A4TSHRCASP1SMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | CYP3A4 622/4885TSHR 4609/4885CASP1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.